JP2010528047A5 - - Google Patents

Download PDF

Info

Publication number
JP2010528047A5
JP2010528047A5 JP2010509554A JP2010509554A JP2010528047A5 JP 2010528047 A5 JP2010528047 A5 JP 2010528047A5 JP 2010509554 A JP2010509554 A JP 2010509554A JP 2010509554 A JP2010509554 A JP 2010509554A JP 2010528047 A5 JP2010528047 A5 JP 2010528047A5
Authority
JP
Japan
Prior art keywords
composition
antibody
factor
antagonist
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010509554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528047A (ja
JP5416695B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/064526 external-priority patent/WO2008147883A1/en
Publication of JP2010528047A publication Critical patent/JP2010528047A/ja
Publication of JP2010528047A5 publication Critical patent/JP2010528047A5/ja
Application granted granted Critical
Publication of JP5416695B2 publication Critical patent/JP5416695B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010509554A 2007-05-23 2008-05-22 補体が関係している眼の状態の予防および治療 Expired - Fee Related JP5416695B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
US60/939,791 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013236445A Division JP2014087346A (ja) 2007-05-23 2013-11-15 補体が関係している眼の状態の予防および治療

Publications (3)

Publication Number Publication Date
JP2010528047A JP2010528047A (ja) 2010-08-19
JP2010528047A5 true JP2010528047A5 (https=) 2012-05-10
JP5416695B2 JP5416695B2 (ja) 2014-02-12

Family

ID=39638868

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010509554A Expired - Fee Related JP5416695B2 (ja) 2007-05-23 2008-05-22 補体が関係している眼の状態の予防および治療
JP2013236445A Withdrawn JP2014087346A (ja) 2007-05-23 2013-11-15 補体が関係している眼の状態の予防および治療
JP2016015288A Withdrawn JP2016145205A (ja) 2007-05-23 2016-01-29 補体が関係している眼の状態の予防および治療
JP2017146477A Pending JP2017197577A (ja) 2007-05-23 2017-07-28 補体が関係している眼の状態の予防および治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013236445A Withdrawn JP2014087346A (ja) 2007-05-23 2013-11-15 補体が関係している眼の状態の予防および治療
JP2016015288A Withdrawn JP2016145205A (ja) 2007-05-23 2016-01-29 補体が関係している眼の状態の予防および治療
JP2017146477A Pending JP2017197577A (ja) 2007-05-23 2017-07-28 補体が関係している眼の状態の予防および治療

Country Status (28)

Country Link
US (6) US8007791B2 (https=)
EP (1) EP2152755B1 (https=)
JP (4) JP5416695B2 (https=)
KR (1) KR101540126B1 (https=)
CN (3) CN101754980B (https=)
AR (1) AR066660A1 (https=)
AU (1) AU2008256835B2 (https=)
BR (1) BRPI0811142A8 (https=)
CA (1) CA2683498A1 (https=)
CL (1) CL2008001498A1 (https=)
CY (1) CY1116062T1 (https=)
DK (1) DK2152755T3 (https=)
ES (1) ES2533242T3 (https=)
HK (1) HK1207327A1 (https=)
HR (1) HRP20150281T1 (https=)
IL (2) IL201476A (https=)
MX (1) MX2009012422A (https=)
PE (1) PE20090294A1 (https=)
PH (1) PH12013500992B1 (https=)
PL (1) PL2152755T3 (https=)
PT (1) PT2152755E (https=)
RS (1) RS53901B1 (https=)
RU (2) RU2522976C2 (https=)
SG (1) SG10201401404RA (https=)
SI (1) SI2152755T1 (https=)
TW (2) TWI419704B (https=)
WO (1) WO2008147883A1 (https=)
ZA (1) ZA200907028B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261103B2 (en) * 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
EP3299027A1 (en) * 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
CN106188303A (zh) 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2010026121A1 (en) * 2008-09-02 2010-03-11 Novartis Ag Bicyclic kinase inhibitors
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
SI2600812T1 (sl) * 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
DK2635704T3 (en) * 2010-11-01 2017-06-19 Hoffmann La Roche Predicting progression to advanced age-related macular degeneration using a polygenic score
EP2661433B1 (en) 2011-01-04 2017-08-16 Novartis AG Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
WO2015054298A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
JP2016539098A (ja) * 2013-10-25 2016-12-15 チルドレンズ メディカル センター コーポレーション 網膜の血管障害を治療又は予防する方法
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
WO2017053753A1 (en) * 2015-09-23 2017-03-30 Sangamo Biosciences, Inc. Htt repressors and uses thereof
HK1257425A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 测量因子d活性和因子d抑制剂效力的方法
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017075252A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
KR102162324B1 (ko) 2015-10-30 2020-10-07 제넨테크, 인크. 항-HtrA1 항체 및 이의 사용 방법
MX2018007392A (es) * 2015-12-23 2018-08-15 Greenovation Biotech Gmbh Polipeptidos para inhibir la activacion del complemento.
EP3405577B8 (en) * 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
EP3580241A4 (en) * 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania ANTIFACTOR D ANTIBODIES AND USES THEREOF
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009778A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods for culturing mesenchymal stem cells, products thereof, and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) * 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2288649T3 (es) 1997-11-21 2008-01-16 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
EP1053245A4 (en) 1998-02-09 2002-04-17 Human Genome Sciences Inc 45 HUMAN SECRETED PROTEINS
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
BR9909220A (pt) 1998-02-20 2000-11-21 Tanox Inc Inibidores de ativação de complemento
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
KR100468978B1 (ko) 1998-12-16 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
DE69930872T8 (de) * 1998-12-21 2007-05-03 Ludwig Institute For Cancer Research Antikörper gegen verkürzten vegf-d und deren verwendungen
JP3993746B2 (ja) 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ514091A (en) 1999-03-11 2004-01-30 Rmf Dictagene S Vascular adhesion molecules and modulation of their function
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
WO2001036102A1 (en) 1999-11-02 2001-05-25 Uliyanovsky Gosudarstvenny Tekhnichesky Universitet Method for cleaning liquids of ferromagnetic particles and device for the implementation thereof
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １８個のヒト分泌タンパク質
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2416538A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP3299027A1 (en) * 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN106188303A (zh) * 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Similar Documents

Publication Publication Date Title
JP2010528047A5 (https=)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP7695187B2 (ja) ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
US20220162296A1 (en) Personalized treatment of ophthalmologic diseases
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
JP2011504872A5 (https=)
JP5990511B2 (ja) 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体
JP2016504416A5 (https=)
JP2020535184A5 (https=)
RU2008144802A (ru) Применение антител против ил-1 для лечения глазных расстройств
JP2017535285A5 (https=)
JP2014532072A5 (https=)
JP2017502023A (ja) 眼疾患を治療する組成物および方法
JP2015503909A5 (https=)
EP2200699A1 (en) Antigen binding proteins
JP2011503094A5 (https=)
JP2021520195A5 (https=)
JP2018530574A5 (https=)
RU2018103960A (ru) Антитела против ang-2, содержащие только тяжелую цепь
JP2018527327A5 (https=)
JP2025114621A (ja) 神経変性疾患を治療するための改変抗ｐｄ－ｌ１抗体および治療方法および使用
WO2023001288A1 (zh) 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用
TW202237181A (zh) 治療眼部疾病之方法
JP2018523673A5 (https=)
JP7382343B2 (ja) Ｍｆａｐ４に対する抗体